CASI Dividend: CASI Pharmaceuticals Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

CASI Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	31	28	33	43	30	15
Revenue Growth (YoY)	35%	-15%	-23%	43%	100%	275%
Cost of Revenue	13	12	13	15	12	9
Gross Profit	17	15	20	27	17	5
Selling, General & Admin	45	41	41	37	38	27
Research & Development	--	8	9	15	14	11
Operating Expenses	60	50	45	53	52	38
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-43	-38	-26	-37	-35	-47
Income Tax Expense	--	0	0	1	0	--
Net Income	-46	-39	-26	-41	-36	-48
Net Income Growth	70%	50%	-37%	14%	-25%	4%
Shares Outstanding (Diluted)	16	15.34	13.36	13.64	13.61	11.04
Shares Change (YoY)	18%	15%	-2%	0%	23%	15%
EPS (Diluted)	-2.9	-2.56	-2.02	-3.01	-2.69	-4.37
EPS Growth	43%	27%	-33%	12%	-38%	-9%
Free Cash Flow	--	-29	-22	-26	-42	-45
Free Cash Flow Per Share	--	-1.89	-1.64	-1.9	-3.08	-4.07
Gross Margin	54.83%	53.57%	60.6%	62.79%	56.66%	33.33%
Operating Margin	-135.48%	-121.42%	-75.75%	-60.46%	-116.66%	-220%
Profit Margin	-148.38%	-139.28%	-78.78%	-95.34%	-120%	-320%
Free Cash Flow Margin	--	-103.57%	-66.66%	-60.46%	-140%	-300%
EBITDA	--	-34	-22	-24	-34	-32
EBITDA Margin	--	-121.42%	-66.66%	-55.81%	-113.33%	-213.33%
D&A For EBITDA	--	0	3	2	1	1
EBIT	-42	-34	-25	-26	-35	-33
EBIT Margin	-135.48%	-121.42%	-75.75%	-60.46%	-116.66%	-220%
Effective Tax Rate	--	0%	0%	-2.7%	0%	--